TD Cowen Has Lowered Expectations for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Posted by Francis Steltz on Aug 8th, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its target price decreased by investment analysts at TD Cowen from $145.00 to $140.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price objective points to a potential upside of 39.10% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday. Evercore reaffirmed an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Finally, Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.33.

Read Our Latest Analysis on MIRM

Mirum Pharmaceuticals Stock Up 6.9%

Shares of MIRM stock opened at $100.65 on Thursday. The stock’s fifty day moving average price is $110.33 and its 200 day moving average price is $101.79. Mirum Pharmaceuticals has a 1-year low of $57.79 and a 1-year high of $130.00. The company has a market cap of $6.14 billion, a price-to-earnings ratio of -6.92 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s revenue was up 37.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.12) EPS. On average, research analysts expect that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer directly owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This trade represents a 10.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $134,139.46. This represents a 59.09% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock valued at $7,185,662 in the last 90 days. 8.32% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its position in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the period. BlackRock Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth about $513,945,000. Vanguard Group Inc. raised its holdings in Mirum Pharmaceuticals by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock valued at $205,065,000 after buying an additional 50,720 shares during the period. State Street Corp lifted its position in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after buying an additional 797,088 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Mirum Pharmaceuticals by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after buying an additional 137,087 shares during the last quarter.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.